Previous 10 | Next 10 |
ANN ARBOR, Mich., June 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies Global Healthcare Conference on June 8 th , 2022. A live audio webcast can be access...
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholde...
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s research into efficacy of bempedoic acid in patients wi...
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24 th , 2022. A ...
Esperion Therapeutics reported their Q1 earnings that revealed a beat on EPS and revenue. The company reported $13.4M in U.S. product revenue for Q1, which was up around 109% year-over-year. Esperion had a 32% year-over-year cost savings of the company operating expenses compared ...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Esperion Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Esperion Therapeutics, Inc. (ESPR) Q1 2022 Earnings Conference Call May 3, 2022 08:00 ET Company Participants Tiffany Aldrich - Senior Manager, Corporate Communications Sheldon Koenig - President and Chief Executive Officer Joanne Foody - Chief Medical Officer Eric Warren - Chief Commercial O...
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR) Q1 2022 Earnings Call May 03, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics (ESPR) Q1 2022 Earnings Call Transcript
Esperion (NASDAQ:ESPR) stock rose May 3 after Q1 results beat analysts' estimates. Q1 total revenues increased +136% Y/Y to ~$18.84M Y/Y. U.S. net product revenue of cholesterol lowering therapies Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid and ezetimibe) tablets...
Esperion Therapeutics press release (NASDAQ:ESPR): Q1 GAAP EPS of -$0.93 beats by $0.11. Revenue of $18.83M (+135.4% Y/Y) beats by $3.42M. For further details see: Esperion Therapeutics GAAP EPS of -$0.93 beats by $0.11, revenue of $18.83M beats by $3.42M
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...